Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Asset Writedowns and Impairment: 2009-2023

Historic Asset Writedowns and Impairment for UNITED THERAPEUTICS (UTHR) over the last 9 years, with Dec 2023 value amounting to $3.6 million.

  • UNITED THERAPEUTICS's Asset Writedowns and Impairment was N/A to $4.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $130.0 million, marking a year-over-year change of. This contributed to the annual value of $3.6 million for FY2023, which is 67.86% down from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Asset Writedowns and Impairment of $3.6 million as of FY2023, which was down 67.86% from $11.2 million recorded in FY2022.
  • UNITED THERAPEUTICS's 5-year Asset Writedowns and Impairment high stood at $113.4 million for FY2021, and its period low was $3.6 million during FY2023.
  • Over the past 3 years, UNITED THERAPEUTICS's median Asset Writedowns and Impairment value was $11.2 million (recorded in 2022), while the average stood at $42.7 million.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Asset Writedowns and Impairment surged by 2,000.00% in 2021, and later slumped by 90.12% in 2022.
  • Over the past 5 years, UNITED THERAPEUTICS's Asset Writedowns and Impairment (Yearly) stood at $17.2 million in 2019, then tumbled by 68.60% to $5.4 million in 2020, then spiked by 2,000.00% to $113.4 million in 2021, then tumbled by 90.12% to $11.2 million in 2022, then tumbled by 67.86% to $3.6 million in 2023.